CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 913 enrolled
Drug / intervention
HZ/su vaccine GSK1437173A +1 morebiological
Likely dose
HZ/su vaccine GSK1437173A 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03439657
NCT03439657Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

GlaxoSmithKline·interventional·Posted Feb 20, 2018·Updated Jan 11, 2022

In Brief

A Phase 3 clinical trial evaluating HZ/su vaccine GSK1437173A and Prevenar13 for Herpes Zoster. Completed, enrolled 913 participants across 13 sites in 4 countries.

Detailed Summary

The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as compared to the control group where the two HZ/su doses are administered subsequent to Prevenar13.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesCanada, Estonia, Germany, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 20, 2018
Enrollment StartApr 12, 2018
Primary CompletionMay 6, 2019
Study CompletionMar 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.4 years ago

Interventions

HZ/su vaccine GSK1437173Abiological

2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.

Prevenar13biological

1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.